BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36111834)

  • 21. Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway.
    Hobbs H; Bravi G; Campbell I; Convery M; Davies H; Inglis G; Pal S; Peace S; Redmond J; Summers D
    J Med Chem; 2019 Aug; 62(15):6972-6984. PubMed ID: 31283227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requirement for PIKfyve enzymatic activity in acute and long-term insulin cellular effects.
    Ikonomov OC; Sbrissa D; Mlak K; Shisheva A
    Endocrinology; 2002 Dec; 143(12):4742-54. PubMed ID: 12446602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIKfyve, a class III lipid kinase, is required for TLR-induced type I IFN production via modulation of ATF3.
    Cai X; Xu Y; Kim YM; Loureiro J; Huang Q
    J Immunol; 2014 Apr; 192(7):3383-9. PubMed ID: 24600036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency.
    Compton LM; Ikonomov OC; Sbrissa D; Garg P; Shisheva A
    Am J Physiol Cell Physiol; 2016 Sep; 311(3):C366-77. PubMed ID: 27335171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIKfyve-Dependent Phosphoinositide Dynamics in Megakaryocyte/Platelet Granule Integrity and Platelet Functions.
    Caux M; Mansour R; Xuereb JM; Chicanne G; Viaud J; Vauclard A; Boal F; Payrastre B; Tronchère H; Severin S
    Arterioscler Thromb Vasc Biol; 2022 Aug; 42(8):987-1004. PubMed ID: 35708031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.
    Logue J; Chakraborty AR; Johnson R; Goyal G; Rodas M; Taylor LJ; Baracco L; McGrath ME; Haupt R; Furlong BA; Soong M; Prabhala P; Horvath V; Carlson KE; Weston S; Ingber DE; DePamphilis ML; Frieman MB
    Commun Biol; 2022 Aug; 5(1):808. PubMed ID: 35962188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of PIKfyve prevents myocardial apoptosis and hypertrophy through activation of SIRT3 in obese mice.
    Tronchere H; Cinato M; Timotin A; Guitou L; Villedieu C; Thibault H; Baetz D; Payrastre B; Valet P; Parini A; Kunduzova O; Boal F
    EMBO Mol Med; 2017 Jun; 9(6):770-785. PubMed ID: 28396567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor.
    Terajima M; Kaneko-Kobayashi Y; Nakamura N; Yuri M; Hiramoto M; Naitou M; Hattori K; Yokota H; Mizuhara H; Higashi Y
    Eur J Pharmacol; 2016 Jun; 780():93-105. PubMed ID: 27001378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
    Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
    J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1.
    Oppelt A; Haugsten EM; Zech T; Danielsen HE; Sveen A; Lobert VH; Skotheim RI; Wesche J
    Biochem J; 2014 Aug; 461(3):383-90. PubMed ID: 24840251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
    Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
    PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective insulin-induced activation of class I(A) phosphoinositide 3-kinase in PIKfyve immune complexes from 3T3-L1 adipocytes.
    Sbrissa D; Ikonomov O; Shisheva A
    Mol Cell Endocrinol; 2001 Jul; 181(1-2):35-46. PubMed ID: 11476939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class III PI 3-kinase is the main source of PtdIns3P substrate and membrane recruitment signal for PIKfyve constitutive function in podocyte endomembrane homeostasis.
    Ikonomov OC; Sbrissa D; Venkatareddy M; Tisdale E; Garg P; Shisheva A
    Biochim Biophys Acta; 2015 May; 1853(5):1240-50. PubMed ID: 25619930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The phosphoinositide kinase PIKfyve is vital in early embryonic development: preimplantation lethality of PIKfyve-/- embryos but normality of PIKfyve+/- mice.
    Ikonomov OC; Sbrissa D; Delvecchio K; Xie Y; Jin JP; Rappolee D; Shisheva A
    J Biol Chem; 2011 Apr; 286(15):13404-13. PubMed ID: 21349843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of PIKfyve phosphorylation by insulin and osmotic stress.
    Hill EV; Hudson CA; Vertommen D; Rider MH; Tavaré JM
    Biochem Biophys Res Commun; 2010 Jul; 397(4):650-5. PubMed ID: 20513353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness.
    Dupuis-Coronas S; Lagarrigue F; Ramel D; Chicanne G; Saland E; Gaits-Iacovoni F; Payrastre B; Tronchère H
    J Biol Chem; 2011 Sep; 286(37):32105-14. PubMed ID: 21737449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PIKfyve-ArPIKfyve-Sac3 triad in human breast cancer: Functional link between elevated Sac3 phosphatase and enhanced proliferation of triple negative cell lines.
    Ikonomov OC; Filios C; Sbrissa D; Chen X; Shisheva A
    Biochem Biophys Res Commun; 2013 Oct; 440(2):342-7. PubMed ID: 24070605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages.
    Kim GH; Dayam RM; Prashar A; Terebiznik M; Botelho RJ
    Traffic; 2014 Oct; 15(10):1143-63. PubMed ID: 25041080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
    Sano O; Kazetani K; Funata M; Fukuda Y; Matsui J; Iwata H
    FEBS Lett; 2016 Jun; 590(11):1576-85. PubMed ID: 27135648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
    Ikonomov OC; Sbrissa D; Shisheva A
    Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.